MA35864B1 - Analogues du glucagon - Google Patents
Analogues du glucagonInfo
- Publication number
- MA35864B1 MA35864B1 MA37205A MA37205A MA35864B1 MA 35864 B1 MA35864 B1 MA 35864B1 MA 37205 A MA37205 A MA 37205A MA 37205 A MA37205 A MA 37205A MA 35864 B1 MA35864 B1 MA 35864B1
- Authority
- MA
- Morocco
- Prior art keywords
- glucagon
- compounds
- treatment
- vis
- analogues
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 abstract 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 abstract 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 abstract 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 abstract 1
- 101500028775 Homo sapiens Glucagon Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002641 glycemic effect Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161579888P | 2011-12-23 | 2011-12-23 | |
| PCT/EP2012/076137 WO2013092703A2 (en) | 2011-12-23 | 2012-12-19 | Glucagon analogues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35864B1 true MA35864B1 (fr) | 2014-12-01 |
Family
ID=47594620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37205A MA35864B1 (fr) | 2011-12-23 | 2014-07-11 | Analogues du glucagon |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20130316941A1 (OSRAM) |
| EP (1) | EP2793931A2 (OSRAM) |
| JP (1) | JP2015502380A (OSRAM) |
| KR (1) | KR20140114845A (OSRAM) |
| CN (1) | CN104144696A (OSRAM) |
| AP (2) | AP2014007797A0 (OSRAM) |
| AU (1) | AU2012357739A1 (OSRAM) |
| BR (1) | BR112014015681A2 (OSRAM) |
| CA (1) | CA2858949A1 (OSRAM) |
| EA (1) | EA201490982A1 (OSRAM) |
| HK (1) | HK1200369A1 (OSRAM) |
| IL (1) | IL232800A0 (OSRAM) |
| IN (1) | IN2014CN04401A (OSRAM) |
| MA (1) | MA35864B1 (OSRAM) |
| MX (1) | MX2014007120A (OSRAM) |
| PE (1) | PE20142113A1 (OSRAM) |
| PH (1) | PH12014501336A1 (OSRAM) |
| SG (1) | SG11201403377QA (OSRAM) |
| TN (1) | TN2014000224A1 (OSRAM) |
| WO (1) | WO2013092703A2 (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| US9169310B2 (en) | 2010-06-24 | 2015-10-27 | Zealand Pharma A/S | Glucagon analogues |
| JP6228187B2 (ja) | 2012-05-03 | 2017-11-08 | ジーランド ファーマ アクティーゼルスカブ | Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法 |
| EP2664374A1 (en) * | 2012-05-15 | 2013-11-20 | F. Hoffmann-La Roche AG | Lysin-glutamic acid dipeptide derivatives |
| MX356957B (es) | 2012-07-23 | 2018-06-20 | Zealand Pharma As | Analogos del glucagon. |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| MX362190B (es) | 2012-12-21 | 2019-01-08 | Sanofi Sa | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon. |
| GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| CA2926314C (en) * | 2013-10-17 | 2023-08-29 | Zealand Pharma A/S | Acylated glucagon analogues |
| AU2014345569B2 (en) | 2013-11-06 | 2020-08-13 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| CN105829339B (zh) | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
| JOP20200119A1 (ar) * | 2015-01-09 | 2017-06-16 | Lilly Co Eli | مركبات مساعد مشترك من gip وglp-1 |
| SG11201705640PA (en) | 2015-02-17 | 2017-08-30 | Lilly Co Eli | Nasal powder formulation for treatment of hypoglycemia |
| JP6769984B2 (ja) | 2015-03-18 | 2020-10-14 | ジーランド ファーマ アクティーゼルスカブ | アミリン類似体 |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| CA2980978A1 (en) | 2015-04-16 | 2016-10-20 | Zealand Pharma A/S | Acylated glucagon analogue |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| WO2017214543A1 (en) | 2016-06-09 | 2017-12-14 | Amidebio, Llc | Glucagon analogs and methods of use thereof |
| PE20190414A1 (es) | 2016-08-05 | 2019-03-19 | Boehringer Ingelheim Int | Derivados de oxadiazolopiridina para el uso como inhibidores de ghrelin o-aciltransferasa (goat) |
| US10071140B2 (en) | 2016-09-09 | 2018-09-11 | Zealand Pharma A/S | Amylin analogues |
| RU2753193C2 (ru) * | 2016-12-09 | 2021-08-12 | Зилэнд Фарма А/С | Ацилированные двойные агонисты glp-1/glp-2 |
| US11236142B2 (en) * | 2017-08-16 | 2022-02-01 | Dong-A St Co., Ltd. | Acylated oxyntomodulin peptide analog |
| CA3087827A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
| US11136337B2 (en) | 2018-02-02 | 2021-10-05 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
| EP3746451B1 (en) | 2018-02-02 | 2023-07-12 | Boehringer Ingelheim International GmbH | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
| MX2020007994A (es) | 2018-02-02 | 2020-09-09 | Boehringer Ingelheim Int | Derivados de triazolopirimidina para usar como inhibidores de ghrelin o-aciltransferasa (goat). |
| CN111349155B (zh) * | 2018-12-24 | 2022-04-05 | 浙江和泽医药科技股份有限公司 | 一种胰高血糖素类似物及其制备方法和用途 |
| TWI771669B (zh) | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | 製備穩定胜肽調配物之方法 |
| EP4058047A1 (en) | 2019-11-11 | 2022-09-21 | Boehringer Ingelheim International GmbH | Npy2 receptor agonists |
| EP4153600B1 (en) | 2020-05-22 | 2024-08-07 | Boehringer Ingelheim International GmbH | Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
| WO2021233882A1 (en) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
| CN113292646B (zh) * | 2020-05-29 | 2022-05-13 | 东莞云璟生物技术有限公司 | Glp-1/胰高血糖素双重激动剂融合蛋白 |
| KR20230045088A (ko) | 2020-08-07 | 2023-04-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 가용성 npy2 수용체 작용제 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL128829A (en) | 1996-09-09 | 2005-08-31 | Zealand Pharma As | Solid phase sythesis of peptides with pre-sequences |
| IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| SI1891105T1 (sl) | 2005-06-13 | 2012-07-31 | Imp Innovations Ltd | Analogi oksintomodulina in njihovi učinki na prehranjevalno vedenje |
| WO2007100535A2 (en) | 2006-02-22 | 2007-09-07 | Merck & Co., Inc. | Oxyntomodulin derivatives |
| ES2673822T3 (es) | 2006-07-18 | 2018-06-25 | Sanofi | Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer |
| KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| JP5753779B2 (ja) | 2008-06-17 | 2015-07-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体 |
| JP5775450B2 (ja) | 2008-06-17 | 2015-09-09 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴン／ｇｌｐ−１受容体コアゴニスト |
| BRPI0823377A2 (pt) * | 2008-12-15 | 2016-09-27 | Zealand Pharma As | análogos de glucagon |
| JP6054742B2 (ja) * | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| EA026384B1 (ru) * | 2010-01-20 | 2017-04-28 | Зилэнд Фарма А/С | Лечение заболеваний сердца |
| UY33462A (es) * | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
-
2012
- 2012-12-19 SG SG11201403377QA patent/SG11201403377QA/en unknown
- 2012-12-19 US US13/720,041 patent/US20130316941A1/en not_active Abandoned
- 2012-12-19 AU AU2012357739A patent/AU2012357739A1/en not_active Abandoned
- 2012-12-19 KR KR1020147020623A patent/KR20140114845A/ko not_active Withdrawn
- 2012-12-19 HK HK15101109.9A patent/HK1200369A1/xx unknown
- 2012-12-19 PE PE2014000970A patent/PE20142113A1/es not_active Application Discontinuation
- 2012-12-19 MX MX2014007120A patent/MX2014007120A/es unknown
- 2012-12-19 WO PCT/EP2012/076137 patent/WO2013092703A2/en not_active Ceased
- 2012-12-19 AP AP2014007797A patent/AP2014007797A0/xx unknown
- 2012-12-19 CA CA2858949A patent/CA2858949A1/en not_active Abandoned
- 2012-12-19 CN CN201280063090.8A patent/CN104144696A/zh active Pending
- 2012-12-19 EP EP12816470.4A patent/EP2793931A2/en not_active Withdrawn
- 2012-12-19 JP JP2014547973A patent/JP2015502380A/ja active Pending
- 2012-12-19 EA EA201490982A patent/EA201490982A1/ru unknown
- 2012-12-19 BR BR112014015681A patent/BR112014015681A2/pt not_active IP Right Cessation
- 2012-12-19 IN IN4401CHN2014 patent/IN2014CN04401A/en unknown
-
2014
- 2014-05-21 TN TNP2014000224A patent/TN2014000224A1/en unknown
- 2014-05-26 IL IL232800A patent/IL232800A0/en unknown
- 2014-06-11 PH PH12014501336A patent/PH12014501336A1/en unknown
- 2014-07-09 AP AP2014007774A patent/AP2014007774A0/xx unknown
- 2014-07-11 MA MA37205A patent/MA35864B1/fr unknown
-
2016
- 2016-08-17 US US15/239,154 patent/US20160347813A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TN2014000224A1 (en) | 2015-09-30 |
| SG11201403377QA (en) | 2014-07-30 |
| PH12014501336A1 (en) | 2014-09-15 |
| IN2014CN04401A (OSRAM) | 2015-09-04 |
| AP2014007797A0 (en) | 2014-07-31 |
| HK1200369A1 (en) | 2015-10-09 |
| US20160347813A1 (en) | 2016-12-01 |
| JP2015502380A (ja) | 2015-01-22 |
| AP2014007774A0 (en) | 2014-07-31 |
| WO2013092703A2 (en) | 2013-06-27 |
| MX2014007120A (es) | 2015-03-05 |
| US20130316941A1 (en) | 2013-11-28 |
| AU2012357739A1 (en) | 2014-07-03 |
| WO2013092703A3 (en) | 2013-11-14 |
| PE20142113A1 (es) | 2014-12-03 |
| KR20140114845A (ko) | 2014-09-29 |
| CN104144696A (zh) | 2014-11-12 |
| EP2793931A2 (en) | 2014-10-29 |
| BR112014015681A2 (pt) | 2019-09-24 |
| EA201490982A1 (ru) | 2015-01-30 |
| IL232800A0 (en) | 2014-07-31 |
| CA2858949A1 (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35864B1 (fr) | Analogues du glucagon | |
| PH12022550232A1 (en) | Gipr-agonist compounds. | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| EA201290027A1 (ru) | Ацилированные аналоги глюкагона | |
| ZA202109042B (en) | Methods of reducing serum levels of fc-containing agents using fcrn antagonists | |
| MX2010009190A (es) | Anticuerpos anti-c5ar humanizados. | |
| EA201070596A1 (ru) | Гуманизированные антитела против tl1a | |
| MA37983A1 (fr) | Analogues du glucagon | |
| EA201291234A1 (ru) | Аналоги глюкагона | |
| AU2018256498A1 (en) | Antibodies to amyloid beta | |
| SG196839A1 (en) | Antibodies against fcrn and use thereof | |
| MY184241A (en) | Human antibodies to gfr?3 and methods of use thereof | |
| HK1210792A1 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
| MY156337A (en) | Agonist dr5 binding polypeptides | |
| EA201190054A1 (ru) | Аналоги глюкагона | |
| EA201190047A1 (ru) | Аналоги глюкагона | |
| WO2010032059A3 (en) | Antibodies directed to cd105 and uses thereof | |
| WO2010017103A3 (en) | Fully human anti-human nkg2d monoclonal antibodies | |
| MX2009003093A (es) | Composiciones y metodos relacionados con anticuerpos del receptor de glucagon. | |
| EA201490790A1 (ru) | Пептидные конъюгаты агониста рецептора гастрина и глюкагон подобного пептида 1 | |
| EA200901067A1 (ru) | Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов | |
| TN2011000667A1 (en) | Acylated glucagon analogues |